 Neuroprotective Agents
"Neuroprotective Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
| Descriptor ID |
D018696
|
| MeSH Number(s) |
D27.505.696.706.548 D27.505.954.427.575
|
| Concept/Terms |
Neuroprotective Agents- Neuroprotective Agents
- Agents, Neuroprotective
- Neuroprotectants
- Neuroprotective Drugs
- Drugs, Neuroprotective
Neuroprotective Effect- Neuroprotective Effect
- Effect, Neuroprotective
- Neuroprotective Effects
- Effects, Neuroprotective
|
Below are MeSH descriptors whose meaning is more general than "Neuroprotective Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuroprotective Agents".
This graph shows the total number of publications written about "Neuroprotective Agents" by people in this website by year, and whether "Neuroprotective Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 1 | 2 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 3 | 0 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 0 | 3 | | 2007 | 4 | 0 | 4 | | 2008 | 3 | 0 | 3 | | 2009 | 4 | 2 | 6 | | 2010 | 8 | 0 | 8 | | 2011 | 7 | 2 | 9 | | 2012 | 5 | 0 | 5 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 2 | 4 | | 2015 | 2 | 4 | 6 | | 2016 | 4 | 0 | 4 | | 2017 | 2 | 0 | 2 | | 2018 | 5 | 2 | 7 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2021 | 3 | 0 | 3 | | 2022 | 1 | 0 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles.
-
Brown CN, Blaine RE, Barker CM, Coultrap SJ, Bayer KU. The neuroprotective ?-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIa autophosphorylation at T286 or binding to GluN2B. Mol Pharmacol. 2025 Apr; 107(4):100029.
-
Latham AS, Rocha SM, McDermott CP, Reigan P, Slayden RA, Tjalkens RB. Neuroprotective efficacy of the glucocorticoid receptor modulator PT150 in the rotenone mouse model of Parkinson's disease. Neurotoxicology. 2024 Jul; 103:320-334.
-
Kompella UB. 2021 JOPT Award in Science: Dr. B?rbel Rohrer's Research on Mitochondria-Targeted Neuroprotective Drugs. J Ocul Pharmacol Ther. 2022 11; 38(9):591.
-
Neumann NR, Thompson DC, Vasiliou V. AMPK activators for the prevention and treatment of neurodegenerative diseases. Expert Opin Drug Metab Toxicol. 2021 Oct; 17(10):1199-1210.
-
Polutchko SK, Glime GNE, Demmig-Adams B. Synergistic Action of Membrane-Bound and Water-Soluble Antioxidants in Neuroprotection. Molecules. 2021 Sep 04; 26(17).
-
Hermes DJ, Yadav-Samudrala BJ, Xu C, Paniccia JE, Meeker RB, Armstrong ML, Reisdorph N, Cravatt BF, Mackie K, Lichtman AH, Ignatowska-Jankowska BM, Lysle DT, Fitting S. GPR18 drives FAAH inhibition-induced neuroprotection against HIV-1 Tat-induced neurodegeneration. Exp Neurol. 2021 07; 341:113699.
-
Liang LP, Fulton R, Bradshaw-Pierce EL, Pearson-Smith J, Day BJ, Patel M. Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism. J Pharmacol Exp Ther. 2021 04; 377(1):1-10.
-
Mallah K, Couch C, Borucki DM, Toutonji A, Alshareef M, Tomlinson S. Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here? Front Immunol. 2020; 11:2021.
-
Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
-
Sampath D, Lam PM, Laoprasert M, Diaz MJ, Busquet N, White AM, Gonzalez MI, Raol YH. Effects of a potassium channel opener on brain injury and neurologic outcomes in an animal model of neonatal hypoxic-ischemic injury. Pediatr Res. 2020 08; 88(2):202-208.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|